Samsung Bioepis Announces Four-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab-dttb) in Early or Locally Advanced HER2-positive Breast Cancer
Data to be presented at the ASCO20 Virtual Scientific Program Four-year event-free survival (EFS) and…